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ABSTRACT: This work aims to evaluate the potential use of insulin-like growth
factor 2 (IGF-2) as the dominant thymic self-antigen precursor of the insulin
family in designing a tolerogenic approach to type 1 diabetes (T1D) prevention.
This evaluation was primarily based on cytokine profile driven by MHC pre-
sentation of insulin and IGF-2–derived antigens to PBMC cultures derived
from 16 T1D DQ8+ adolescents. Insulin B9-23, one dominant -cell
autoantigen, and the homologous sequence B11-25 of IGF-2 display the same
affinity and fully compete for binding to DQ8, a MHC-II allele conferring ma-
jor genetic susceptibility to type 1 diabetes (T1D). However, compared to insu-
lin B9-23, presentation of IGF-2 B11-25 elicits a suppressive/regulatory
cytokine profile with a higher number of IL-10–secreting cells (P < 0.05), a
much higher ratio of IL-10/IFN- (P < 0.01), as well as a lower number of IL-
4–secreting cells (P < 0.05). Thus, with regard to T1D prevention, administra-
tion of IGF-2–derived self-antigen(s) seems to be an efficient approach that
combines both antagonism for binding to a major susceptibility MHC-II allele,
as well as downstream promotion of an antigen-driven tolerogenic response.
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INTRODUCTION
Although the major autoantigens targeted in type 1 diabetes (T1D) have been
identified, the origin of the autoimmune response directed against islet β cells re-
mains quite obscure. For a long time, autoimmune diseases were thought to result
from a spontaneous or infection-derived breakdown of peripheral self-tolerance.
Such mechanisms, however, were based on the misconception that β cell autoanti-
gens are sequestered from T cells during establishment of self-tolerance in the thy-
mus. This concept of a topographic seclusion of pre-T cells from islet-specific
autoantigens is now obsolete since the thymus parenchyma was demonstrated to be
the site for transcription of genes belonging to several neuroendocrine families or
encoding a variety of tissue-specific antigen precursors.1–8
A logical question derived from the elucidation of the prominent role of the thy-
mus in self-tolerance to neuroendocrine self-principles: Could the development of β
cell autoimmunity result from a thymus dysfunction in the establishment of β cell
tolerance? That hypothesis was supported by a series of previous experimental data.
Neonatal thymectomy prevents the incidence of autoimmune diabetes in the Bio-
Breeding (BB) rat.9 Grafts of thymus or thymic epithelium from the NOD mouse in-
duce insulitis and sialitis in grafted recipients.10,11 Insulin (Ins) and insulin-like
growth factor 1 (Igf1) gene transcripts are detected in all thymi of diabetes-prone
(BBDP) and diabetes-resistant (BBDR) BB rats. While present in the thymus of
BBDR rats, Igf2 transcripts are contrastingly absent in the thymus of more than 80%
of BBDP rats in close concordance with the incidence of diabetes in BBDP rats
(86%). This defect of Igf2 transcription is thymus-specific since Igf2 mRNAs are de-
tected in the liver and the brain of BBDP rats.12 In addition, the levels of INS tran-
scripts are low in the thymus from deceased fetuses with genetic susceptibility to
T1D (presence of VNTR class I alleles, see below), while they are higher in thymi
from fetuses bearing protective alleles (VNTR class III alleles).13,14 Expression of
Ins is also low in the thymus of NOD mice,15 while mice with thymus-restricted
insulin defect develop a strong proinsulin-specific T cell reactivity.16 Breeding of
Ins2−/− onto NOD mice accelerates the development of autoimmune diabetes.17 At
the opposite, insulitis and diabetes are considerably reduced in Ins1−/− congenic
NOD mice.18 This may be explained by the dominance of Ins2 expression in the mu-
rine thymus, while Ins1 is dominantly transcribed in murine islet ß cells. With regard
to other ß cell autoantigens, GAD67 is the dominant GAD isoform expressed in the
thymus, whereas GAD65 is the autoantigen implicated in the peripheral diabetoge-
nic autoimmunity against β cells.19,20 An alternative splicing of IA2 occurs in the
thymus and this leads to the intrathymic presentation of IA-2 antigens different from
those involved in the peripheral autoimmune reaction directed to islet β cells.21 A
specific processing of preprotachykinin A (PPT-A) also takes place in thymic epi-
thelium since only neurokinin A— but not substance P, also derived from PPT-A—
is detected in thymic epithelial cells (TECs).22 It is thus fundamental now to consid-
er the existence of thymus-specific processing pathways, leading to the presentation
of self-antigens that are not identical, but closely homologous to peripheral
autoantigens.
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SELF-VACCINATION AS A NOVEL AVENUE FOR 
T1D PREVENTION AND CURE
Given the impossibility of modifying the genetic constitution of susceptible indi-
viduals and to act upon most of the environmental influences—except perhaps
through a future anti-coxsackievirus vaccination in countries with high T1D inci-
dence—contemporary research still privileges a regulatory approach aiming to con-
trol the specific autoimmune response oriented against β cells, without
compromising general immunity. Ideally, this autoimmune regulation could be com-
bined with strategies aiming at the regeneration of damaged β cells and the inhibition
of the apoptotic process raised in ß cells by the autoimmune process.23 Even after
transplantation of β cells from allogenic and xenogenic donors, or β cells issued
from appropriate differentiation of stem cells, the control of the autoimmune mem-
ory against islet β cells is an absolute requirement both for prevention and cure of
T1D.
According to the recent knowledge gained in T1D pathophysiology and in the
central role of the thymus for establishment of islet β cell self-tolerance, such regu-
lation of the autoimmune process could be obtained by (re)programming β cell tol-
erance through the potent tolerogenic properties of the thymus, in particular the
thymic repertoire of neuroendocrine self-antigen precursors. In this perspective, the
FIGURE 1. Self-vaccination as a novel strategy for prevention and cure of autoim-
mune diseases. The basic principle relies on the difference of immune responses elicited by
peripheral autoantigens and homologous self-antigens predominantly expressed in the thy-
mus. The self-vaccination combines antagonism for binding to MHC presentation “pocket”
and a regulatory/tolerogenic response downstream of the self-antigen presentation.
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profile of cytokine secretion was analyzed after presentation of the sequence Insulin
B9-23, a major T1D autoantigen, and the sequence B11-25 derived from IGF-2, the
dominant self-antigen of the insulin family expressed in the thymus. This study was
performed in cultures of peripheral blood mononuclear cells (PBMCs) derived from
DQ8-positive T1D adolescents. First, in collaboration with Kai Wücherpfennig, In-
sulin B9-23 and IGF-2 B11-25 were shown to have the same affinity and to compete
for binding to DQ8. Then, using the ELISPOT methodology, DQ8 presentation of
IGF-2 B11-25 was shown to induce a regulatory profile (↑ IL-10, ↑ IL-10/IFN-γ, ↓
IL-4), significantly different from the profile induced by Insulin B9-23. Such a reg-
ulatory profile could derive from the behavior of IGF-2 B11-25 acting as a natural
altered peptide ligand for insulin-reactive CD4+ T cells, or from the recruitment and
activation of IGF-2-specific Treg. Thus, in contrast with the absence of any tolero-
genic properties for insulin,24–27 IGF-2 and derived epitopes seem to constitute a
very appropriate choice for a novel type of immunotherapy/vaccine associating both
a competition at the level of MHC presentation and a regulatory immune response
downstream (FIG. 1). Preclinical studies with administration of IGF-2 B11-25 to an-
imal models of T1D have not yet been performed, but it is now evident that the use
of such experimental models cannot determine the efficiency of immunointervention
in T1D patients.28 The benefit of an association of these self-peptides with in vitro-
expanded antigen-specific Treg should also be evaluated in the near future.29,30
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